臨床検査68巻1号

2024年01月発行

今月の特集2 補体をめぐる話題

補体標的治療薬

著者： 植田康敬¹

所属機関： ¹大阪大学大学院医学系研究科血液・腫瘍内科

ページ範囲：P.93 - P.101

Point

●補体活性化経路は，古典経路，第2経路，レクチン経路の3経路により活性化され，C3の活性化を経て終末経路での膜侵襲複合体（MAC）形成に至る．

●C5阻害薬エクリズマブの発作性夜間ヘモグロビン尿症（PNH）における成功の後，C5a受容体（C5aR）阻害薬，C1s抗体薬，C3阻害薬などさまざまな抗補体薬が登場している．

●今後，抗補体薬の開発の進展とともに，さまざまな疾患の病態形成における補体の関与が明らかとなり，抗補体薬の有効性が期待できる対象患者の層別化が進むことが期待される．

参考文献

1）Parker C, Omine M, Richards S, et al：Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood　106：3699-3709，2005

2）Risitano AM, Frieri C, Urciuoli E, et al：The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. Immunol Rev　313：262-278，2023

3）Parker CJ, Wiedmer T, Sims PJ, et al：Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest　75：2074-2084，1985

4）Hillmen P, Hall C, Marsh JC, et al：Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med　350：552-559，2004

5）Hillmen P, Muus P, Röth A, et al：Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol　162：62-73，2013

6）Sheridan D, Yu ZX, Zhang Y, et al：Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS One　13：e0195909，2018

7）Kulasekararaj AG, Hill A, Rottinghaus ST, et al：Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood　133：540-549，2019

8）Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al：Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica　106：230-237，2021

9）Kelly RJ, Höchsmann B, Szer J, et al：Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med　373：1032-1039，2015

10）厚生労働科学研究費補助金（難治性疾患政策研究事業）「血液凝固異常症等に関する研究班」非典型溶血性尿毒症症候群（aHUS）診療ガイド改定委員会（編）：非典型溶血性尿毒症症候群（aHUS）診療ガイド2023，東京医学社，2023

11）日本神経学会（監），重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン作成委員会（編）：重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン2022，南江堂，2022

12）Cataland S, Ariceta G, Chen P, et al：Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab. Blood　134（Suppl_1）：1099，2019

13）Nishimura J, Yamamoto M, Hayashi S, et al：Genetic variants in C5 and poor response to eculizumab. N Engl J Med　370：632-639，2014

14）Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al：Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood　125：775-783，2015

15）Liu H, Xia L, Weng J, et al：Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study. Am J Hematol　98：1407-1414，2023

16）Röth A, Nishimura JI, Nagy Z, et al：The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood　135：912-920，2020

17）Schreiber A, Xiao H, Jennette JC, et al：C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol　20：289-298，2009

18）Jayne DRW, Merkel PA, Schall TJ, et al：Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med　384：599-609，2021

19）Röth A, Barcellini W, D'Sa S, et al：Sutimlimab in Cold Agglutinin Disease. N Engl J Med　384：1323-1334，2021

20）Röth A, Berentsen S, Barcellini W, et al：Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood　140：980-991，2022

21）Risitano AM, Notaro R, Marando L, et al：Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood　113：4094-4100，2009

22）Hill A, Rother RP, Arnold L, et al：Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica　95：567-573，2010

23）Hillmen P, Szer J, Weitz I, et al：Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med　384：1028-1037，2021

24）Morgan BP, Gasque P：Extrahepatic complement biosynthesis: where, when and why?. Clin Exp Immunol　107：1-7，1997

25）Ueda Y, Takamori H, Nishimura JI：Pegcetacoplan versus Eculizumab in PNH. N Engl J Med　385：1723-1724，2021

26）Agency EM：Aspaveli: EPAR—Product information，2022（https://www.ema.europa.eu/en/documents/product-information/aspaveli-epar-product-information_en.pdf）（最終アクセス：2023年10月19日）

27）Harboe M, Ulvund G, Vien L, et al：The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol　138：439-446，2004

28）Peffault de Latour R, Roeth A, Kulasekararaj A, et al：Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study. Blood　140（Suppl 2）：LBA-2，2022

29）Peffault de Latour R, Han B, Maciejewski JP, et al：P774: Substantial increases in paroxysmal nocturnal hemoglobinuria (PNH) red blood cell clone size with oral iptacopan monotherapy confirms control of hemolysis in complement inhibitor-naïve PNH patients. Hemasphere　7（Suppl）：e033868c，2023

30）Lee JW, Griffin M, Kim JS, et al：P771: Patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis on ravulizumab/eculizumab showed hemoglobin response superiority with add-on danicopan vs placebo. Hemasphere　7（Suppl）：e777903c，2023

31）Khaled SK, Claes K, Goh YT, et al：Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation—Associated Thrombotic Microangiopathy. J Clin Oncol　40：2447-2457，2022

32）Lafayette RA, Rovin BH, Reich HN, et al：Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney Int Rep　5：2032-2041，2020

33）García-Laorden MI, Hernández-Brito E, Muñoz-Almagro C, et al：Should MASP-2 Deficiency Be Considered a Primary Immunodeficiency? Relevance of the Lectin Pathway. J Clin Immunol　40：203-210，2020